MedTrace Logo

Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

NCT02305979 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2018-07-03

No results posted yet for this study

Summary

The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.

Conditions

Interventions

DRUG

Loratadine

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • LeAnne Kennedy, PharmD · Wake Forest University Health Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02305979 on ClinicalTrials.gov